Twist Bioscience Corp at UBS Genomics 2.0 and MedTech Innovations Summit Transcript

Aug 10, 2022

Click here to view more TWST transcripts

Aug 09, 2022 / 09:00PM GMT
Unidentified Analyst -

All right. So for our next panel here, happy to welcome Twist Biosciences for next fireside chat. With us, we have CFO, Jim Thorburn and Chief Commercial Officer, Patty Finn. Welcome.

James M. Thorburn - Twist Bioscience Corporation - CFO

Yes. I'm the CFO, and I've got the dull Scottish accent. Patty is Chief Commercial Officer and has got a more aggressive accent.

Questions and Answers:

Unidentified Analyst -

All right. So maybe dig in then from that there. So I guess Twist's portfolio touches on several fast-growing areas across antibody discovery, NGS, Synbio. I guess maybe talk from a high level, where do you see the largest near-term and maybe long-term opportunities across the portfolio?

James M. Thorburn - Twist Bioscience Corporation - CFO

Well, we just ended -- we just announced our quarter last week, last Friday seems like a long time ago. Revenue was $56 million for the quarter, and we had bookings orders almost $60 million. So in terms of orders,

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.